Loading...
Loading...
OABIW| Name | Value |
|---|---|
| Revenues | 7.6M |
| Cost of Revenue | 6.1M |
| Gross Profit | 1.5M |
| Operating Expense | 20.3M |
| Operating I/L | -18.8M |
| Other Income/Expense | 3.3M |
| Interest Income | 0.8M |
| Pretax | -15.5M |
| Income Tax Expense | -1.9M |
| Net Income/Loss | -13.6M |
OmniAb, Inc. is a biotechnology company that offers therapeutic antibody discovery technologies in the United States. The company's OmniAb platform utilizes genetically modified animals to produce antibodies with human sequences, facilitating the development of human therapeutic candidates. Their diverse antibody repertoires and screening technologies enable the discovery of next-generation therapeutics. Additionally, OmniAb's OmniFlic and OmniClic address industry needs for bispecific antibody applications through a common light chain approach, while OmniTaur features unique structural attributes of cow antibodies for complex targets.
